Author:

Keywords:

Clinical Protocols, Clinical Trials, Phase II, Controlled Clinical Trials, Fibrinolytic Agents, Humans, Myocardial Infarction, Platelet Glycoprotein GPIIb-IIIa Complex, Research Design, Tissue Plasminogen Activator, Treatment Outcome, Science & Technology, Life Sciences & Biomedicine, Cardiac & Cardiovascular Systems, Cardiovascular System & Cardiology, MOLECULAR-WEIGHT HEPARIN, MYOCARDIAL-INFARCTION, THROMBOLYSIS, Clinical Trials, Phase II as Topic, Controlled Clinical Trials as Topic, 1102 Cardiorespiratory Medicine and Haematology, 1103 Clinical Sciences, Cardiovascular System & Hematology, 3201 Cardiovascular medicine and haematology, 3202 Clinical sciences